Pyrrolo[2,1-f[1,2,4]triazine compounds, preparation methods and applications thereof

A method for treating cancer, comprises:

• administrating to a subject in need thereof an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pyrrolo[2,1-f][1,2,4]triazine compound of formula I,
• wherein,
• X═CH or N;
• R1 is —NR5R6;
• R2 is
• R3 is —NH2, —NHC(O)NHR11, —NHC(O)OR11, —NHC(O)R11, —CH2OH, —CH2S(O)2R12 or —CH2NHS(O)2R12;
• R4 is H or CF3;
• R5 and R6 are each independently a C1-C4 alkyl, or combined with the nitrogen atom to which they are attached to form an unsubstituted 5-8 membered saturated heterocycle or a 5-8 membered saturated heterocycle substituted by a substituent, the substituent is —S(O)2R12;
• R7, R8, R9 and R10 are each independently H or a C1-C3 alkyl, alternatively, R7 and R8, or R9 and R10, with the carbon atoms to which they are attached as bridge carbon atoms, form bridged bicylco-heterocycle with morpholine ring;
• R11 is a C1-C4 alkyl, an unsubstituted C3-C6 cycloalkyl or a C3-C6 cycloalkyl substituted by one or more substituents, an unsubstituted benzyl or a benzyl substituted by one or more substituents, an unsubstituted phenyl or a phenyl substituted by one or more substituents, an unsubstituted isoxazolyl or an isoxazolyl substituted by one or more substituents, or an unsubstituted pyridyl or a pyridyl substituted by one or more substituents, and the one or more substituents are selected from halogen, a C1-C3 alkyl, or a C1-C3 alkoxyl, —CF3, —C(O)OR12, —C(O)NR12R15,
• R12 and R15 are each independently a C1-C3 alkyl;
• or an isomer or a pharmaceutically acceptable salt, ester or hydrate thereof.